News & Updates
Filter by Specialty:
CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.
CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
01 Aug 2024
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
10 Jul 2024
SABR yields better survival, tumour control in oligometastatic HCC
Treatment with stereotactic ablative radiotherapy (SABR) results in excellent local tumour control and improves survival among patients with oligometastatic hepatocellular carcinoma (HCC), with no serious adverse effects, reports a study.
SABR yields better survival, tumour control in oligometastatic HCC
05 Jul 2024
Liver stiffness predicts decompensation, mortality in ALD patients
Clinicians may use liver stiffness measurement (LSM) by transient elastography (TE) to accurately predict decompensation and all-cause mortality in patients with compensated alcohol-related liver disease (ALD), suggests a study.
